Life Sciences Tools and Services
Company Overview of BioAtla, LLC
BioAtla, LLC, a global biology outsourcing services provider, offers protein therapeutics technology and services. It provides target discovery services; and antibody evolution, engineering, and generation services that include antibody affinity maturation and functional engineering, antibody expression and purification, assay development and functional characterization, antibody internalization, antigen expression and purification, monoclonal and polyclonal antibody production, and follow-on biologics services. The company also offers Versitope system that maximizes epitope coverage, affinity, and functionality to deliver the path to discovery of immunization-induced antibodies; GigaMab, a ...
11011 Torreyana Road
San Diego, CA 92121
Founded in 2007
Key Executives for BioAtla, LLC
Chairman and Chief Executive Officer
Founder and Business Advisor
Vice President of Scientific Projects & Collaboration
Compensation as of Fiscal Year 2014.
BioAtla, LLC Key Developments
BioAtla, LLC Completes Engineering of Telephus Medical Antibody TPH 101 for Prevention of Infection in Septic Revision Hip and Knee Arthroplasty
Mar 18 14
BioAtla, LLC announced that BioAtla has successfully completed a key protein engineering phase of Telephus' compound TPH 101. TPH 101 is Telephus' lead program focused on the development of neutralizing antibodies targeting a key bacterial enzyme that drives the formation of antibiotic-resistant biofilm infections on implanted medical devices. BioAtla's proprietary Comprehensive Integrated Antibody Optimization (CIAO!(TM)) platform integrates important features of manufacturing and process development into protein design yielding superior antibody candidates. TPH 101 is designed to prevent devastating orthopedic periprosthetic joint infections and accompanying implant-associated osteomyelitis that can occur in total hip and knee replacement and other arthroplasty procedures. These infections can be medically and financially devastating to patients, with treatment costs that can be 4-6 times the cost of the original operation alone. There are approximately 1.05 million total hip and knee replacement procedures performed annually in the United States today, with those procedures projected to cost nearly $120 billion by 2020. Treatment of periprosthetic joint infections in some patients who undergo these procedures is projected to cost the healthcare system $1.7 billion in that same year.
BioAtla, LLC Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014
Dec 24 13
BioAtla, LLC Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014 . Venue: Westin San Francisco Market Street, San Francisco, California, United States.
Spirogen and BioAtla LLC Present Positive Data on Next-Generation Warheads in ADCs Against Cancer
Apr 8 13
Spirogen and BioAtla LLC announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC. The study evaluated the efficacy of five ADCs against solid and hematological cancer targets. The hematological target antibody was engineered using BioAtla's proprietary CIAO(TM) and BioAcceleration(TM) technologies and conjugated to Spirogen's cytotoxic PBD dimers. Trastuzumab ADCs were tested against Her2-expressing human breast cancer in vivo.
For both tumour types data showed that the ADCs achieved durable complete regression and tumor free survival. The PBD dimers were not found to be cross-resistant with widely-used chemotherapeutic agents.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|